Podcasts about Gilead

Grace never lowers the standards of holiness. Jesus didn't lower the bar, He raised it. Bible in a Year: Job 8-16 & Acts 9:23-34 

In reading our text you have learned that there is a balm in Gilead, that there is a great physician there; He has checcked your fearful, mortal malady, and you shall live forever. Bible in a Year: Job 5-7 & Acts 8:1-25 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The CDC's new vaccine advisors are meeting with an unexpected agenda today, including discussions on topics such as Sanofi and Gilead's protein degrader deals, the FDA's review of Sarepta's gene therapy, and a contentious hearing with RFK Jr. over vaccines. The meeting marks the beginning of a new era for the influential vaccine committee. The FDA has named a psychedelic proponent as CDER deputy director, while Nektar has declared a Phase IIb win for eczema treatment. Experts say conflicts of interest among axed ACIP members are a "red herring," and the pharma industry is facing turmoil in failed immuno-oncology projects. Prescription drug sales are projected to hit $1.75 trillion by 2030, thanks to GLP-1s. Transitioning to the next news, a major pharmaceutical company has announced a breakthrough in cancer research, potentially changing the landscape of treatment options for patients worldwide. This development comes at a time when the industry is seeing significant advancements in personalized medicine and targeted therapies. Moving on to regulatory updates, the FDA has recently approved a new drug for a rare disease, providing hope for patients who previously had limited treatment options. This decision showcases the agency's commitment to expediting the approval process for innovative therapies that address unmet medical needs. In other news, a biotech startup has secured funding for its groundbreaking technology that aims to revolutionize drug delivery methods. This investment highlights the growing interest in novel approaches to drug development and underscores the importance of innovation in the industry.Wrapping up today's episode, we take a look at the latest trends in digital health, with companies leveraging artificial intelligence and big data analytics to improve patient outcomes and streamline healthcare delivery. These technological advancements have the potential to transform the way healthcare is delivered and pave the way for a more efficient and patient-centric system. That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology sectors.

In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. •    Intro :58 •    The interview/about Regueiro 1:03 •    Tell us about your family and where you grew up. 1:24 •    How did you get interested in medicine? 2:16 •    Who were your early influences?  4:18 •    What is the medical home? 5:57 •    How did you develop the idea to apply the medical home model to IBD? 7:45 •    Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 •    Why hasn't this model become standard of care for patients with complex IBD? 14:13 •    What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 •    Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 •    What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 •    What have you learned in this position at Cleveland Clinic? 25:23 •    Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 •    How would you recommend that people prepare for having a position like this? 27:34 •    Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 •    With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 •    What are the challenges that you still see in the ways we are using telehealth? 39:05 •    What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 •    Thank you, Miguel 42:55 •    Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

Navigating the growing complexity of bladder cancer care is essential to improving patient access and treatment closer to home. In this episode, CANCER BUZZ speaks with Suzanne Merrill, MD, urologic oncologist at Colorado Urology about barriers and solutions to delivering high-quality bladder cancer care in community settings. CANCER BUZZ also speaks with Patrick Hensley, MD, urologist at University of Kentucky Markey Cancer Center, about implementing the Delivering High-Quality Bladder Cancer Care infographic in the community setting. Created by ACCC and BCAN, the infographic describes the 10 elements of excellent bladder cancer care. Cancer programs that align their practices with these guidelines can join a public registry so that patients and caregivers can identify quality bladder cancer care close to where they live. “The best strategies and tools to deliver high quality bladder cancer care out in the community lie first and foremost with having a bladder cancer clinician. It could be a urologist, it could be a urologic oncologist, could even be a medical oncologist or a radiation oncologist...their discipline doesn't matter as much as [having] the core clinical expert that is excited and dedicated to developing and instituting a comprehensive bladder cancer program.” - Suzanne Merrill, MD, FACS “Everybody assumes comprehensive care is being delivered at academic university settings, which it is, but there's so much...bladder cancer care being performed out in the community. So [the question is] how can we achieve comprehensive programs out in the community?” - Suzanne Merril, MD, FACS “I think it's really important that subspecialists and community providers work together to streamline those referrals and anticipate when the patients are coming in and what their needs are going to be, from a procedural standpoint, imaging standpoint, etc, so that you can avoid some of those undue delays in diagnosis and treatment.” - Patrick Hensley, MD Suzanne Merrill, MD, FACS Urologic Oncologist Colorado Urology Aurora, CO Patrick Hensley, MD Urologist Markey Cancer Center – Urology University of Kentucky Lexington, KY   Resources: Infographic: Delivering High Quality Cancer Care in the Community Addressing Disparities in Bladder Cancer Care Understanding and Mitigating Disparities in Bladder Cancer Care Bladder Cancer Advocacy Network (BCAN)   Funder Statement This program is supported by Astellas Pfizer Alliance, EMD Serano, and Gilead.

Let the insults begin! This month's JW Broadcast features the graduation ceremony for the 157th Class of Gilead, including the latest installment of their talk show and one, would be king, confessing that some Jehovah's Witnesses are really annoying.  TWITTER: @exjwpodcastINSTAGRAM: survivingparadisepodcast

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

In reading the Old Testament you will learn that there is a balm in Gilead, In reading the New Testament you will learn that the balm is Jesus., Bible in a Year: Esther 1-2 & Acts 5:1-21 Gpys 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Gilead has received approval for a twice-yearly HIV drug, Lenacapavir, which will be marketed as Yeztugo, potentially redefining the prep market. In other news, biopharma deal premiums show intense negotiations, with Sanofi paying a high premium for Vigil Neuroscience and Novartis acquiring Regulus for $800 million upfront. BioNTech is merging with CureVac after previously criticizing its failed COVID vaccine program. AI is becoming crucial in precision oncology, with companies like AstraZeneca and Pfizer using computational power to design trials and understand challenging cancers better. Intellia Therapeutics aims to transform lives with genome editing treatments.

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Die Themen in den Wissensnachrichten: +++ Durch die Erderwärmung werden wir weniger zu Essen haben +++ USA: Neues Medikament zur HIV-Prävention zugelassen +++ Astro-Rätsel um seit dem Urknall vermisste Materie gelöst +++**********Weiterführende Quellen zu dieser Folge:Impacts of climate change on global agriculture accounting for adaptation, Nature, 18.06.2025Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection, Gilead 18.6.25A gas-rich cosmic web revealed by the partitioning of the missing baryons, Nature Astronomy, 16.06.2025Indicators of Global Climate Change 2024: annual update of key indicators of the state of the climate system and human influence. Earth System Science Data 19.6.25Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects, Cell 06.06.25Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

En Estados Unidos, el ente regulador aprobó un nuevo tratamiento inyectable, que podría revolucionar la lucha contra el Virus de Inmunodeficiencia Humana y el sida. Se presentó como Yeztugo, del laboratorio farmacéutico Gilead y el tratamiento consiste en dos inyecciones cada año. Los medicamentos destinados a prevenir la transmisión del VIH existen desde hace más de una década, pero toma una pastilla diaria.

BOOK OF JUDGES Wounded Leaders 6.15.25 Judges 11:1-3 Now Jephthah the Gileadite was a mighty warrior, but he was the son of a prostitute. Gilead was the father of Jephthah. 2 And Gilead's wife also bore him sons. And when his wife's sons grew up, they drove Jephthah out and said to him, “You shall not have an inheritance in our father's house, for you are the son of another woman.” 3 Then Jephthah fled from his brothers and lived in the land of Tob, and worthless fellows collected around Jephthah and went out with him. Judges 11:29-33 Then the Spirit of the Lord was upon Jephthah, and he passed through Gilead and Manasseh and passed on to Mizpah of Gilead, and from Mizpah of Gilead he passed on to the Ammonites. 30 And Jephthah made a vow to the Lord and said, “If you will give the Ammonites into my hand, 31 then whatever comes out from the doors of my house to meet me when I return in peace from the Ammonites shall be the Lord's, and I will offer it up for a burnt offering.” 32 So Jephthah crossed over to the Ammonites to fight against them, and the Lord gave them into his hand. 33 And he struck them from Aroer to the neighborhood of Minnith, twenty cities, and as far as Abel-keramim, with a great blow. So the Ammonites were subdued before the people of Israel. Judges 11:34-35 Then Jephthah came to his home at Mizpah. And behold, his daughter came out to meet him with tambourines and with dances. She was his only child; besides her he had neither son nor daughter. 35 And as soon as he saw her, he tore his clothes and said, “Alas, my daughter! You have brought me very low, and you have become the cause of great trouble to me. For I have opened my mouth to the Lord, and I cannot take back my vow.” Passion or zeal for God, if not rooted in the truth of God's character and the authority of Scripture, can lead to disastrous outcomes. Jephthah reasons with God like a warrior, not a worshipper. Jephthah shows us the consequences of operating in our own wisdom and strength rather than trusting God's character and faithfulness. When a leader carries deep insecurities and unhealed hurt, that pain doesn't remain internal. It leaks into their decisions, relationships, and the culture they create. God's Spirit may empower someone, but that doesn't mean all their actions are good or Spirit-led.

Gilead. Marthas. Handmaids. Eyes. They sound biblical but if they are, where and what do these references mean? Are actual slave women co-opted as surrogate baby providers in the Bible? Do they truly lie in their mistresses' laps to conceive and give birth? What do the Handmaids mean by "Blessed be the fruit"? And who was the original Jezebel? Fans of the show need look no further. This is the Bible of the Handmaid's Tale.Written and produced by Chas Bayfield.Music by Michael Auld and Jon Hawkins MusicCover art by Lisa GoffSend any questions or feedback to contact@whollybuyable.com

Dr. William Soliman is the founder and CEO of the Accreditation Council for Medical Affairs (ACMA). The ACMA is America's leader in life sciences accreditation, certification & training.  Soliman is a former pharmaceutical executive who worked in leadership roles at Merck, Abbvie, Gilead and more. He is considered a pharma industry futurist and has been featured on NewsNation, Fox News, Newsmax, Forbes, Al Jazeera, Yahoo Business TV, ABC News Radio & more. The ACMA established the first ever certification standards in the United States and stands as a benchmark of excellence for prior authorization professionals, reimbursement professionals, pharmaceutical sales professionals, medical science liaisons and medical affairs professionals.  Dr. Soliman received his PhD from Columbia University & his BA from New York University.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. Key Episode Timestamps 00:00:01 Introduction 00:00:45 Efimosfermin Alfa in MASH 00:05:56 PEth Testing 00:13:19 RETRACT-B 00:20:44 Linerixibat in PBC Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. If you haven't already, be sure to check out part 1 here! Key Episode Timestamps 0:00:00 LITMUS Study 0:05:47 Norursodeoxycholic Acid in PSC 0:10:12 GLOBE Score for PBC 0:15:11 Conclusion Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.

Mumbai markets are leading the global pack — but can sky-high valuations in cement and defense stocks hold? Hosted by Michelle Martin with Ryan Huang, we unpack India’s stunning 10% rally and what’s driving the bull run. JPMorgan’s bullish on beaten-down biotech: hear why Eli Lilly, Gilead, Merck, Regeneron, and Bristol Myers are back on their radar. DocuSign gets punished despite strong earnings — what’s spooking investors? Keppel DC REIT climbs back into the STI on AI-data centre bets, while Hello Kitty’s parent Sanrio outpaces Toyota. Plus, the Straits Times Index movers: CDL, Yangzijiang, and DFI Retail. See omnystudio.com/listener for privacy information.

We asked chatGPT,  "Why does it seem like the united states government is against its citizens today?" Here is what the magic 8 ball delivered: https://chatgpt.com/share/682df261-24d4-8012-8a17-a681a60869edInteresting! Because at some point we were not able to inquire! and speaking of not trusting our government: Vietnam War RecommendationsThe Women: Kristin Hannah https://www.goodreads.com/book/show/127305853-the-womenTurning Point Vietnam War: https://slate.com/news-and-politics/2025/04/netflix-vietnam-documentary-turning-point-accuracy.htmlAdriana Smith You and your family are in our thoughts. https://www.tiktok.com/@momofboys211/photo/7505853436932525355South Sudan: https://abcnews.go.com/US/wireStory/judge-orders-us-officials-court-answer-questions-migrants-122028875Support the showThe Parlour with Lori and Lisa comes to you with our takes on current events, politics, human interest stories, all things close to our hearts, and so much MORE! Thank you for following our media journey and be sure to look for us as we roll out in all the social platforms. #SlowMedia

Amos 1:1-2:3 (NASB) 1 The words of Amos, who was among the sheepherders from Tekoa, which he saw in visions concerning Israel in the days of Uzziah king of Judah, and in the days of Jeroboam son of Joash, king of Israel, two years before the earthquake. 2 And he said,“The Lord roars from Zion,And from Jerusalem He utters His voice;And the shepherds' pasture grounds mourn,And the summit of Carmel dries up.” 3 This is what the Lord says:“For three offenses of Damascus, and for four,I will not revoke its punishment,Because they threshed Gilead with iron sledges.4 So I will send fire upon the house of Hazael,And it will consume the citadels of Ben-hadad.5 I will also break the gate bar of Damascus,And eliminate every inhabitant from the Valley of Aven,As well as him who holds the scepter, from Beth-eden;So the people of Aram will be exiled to Kir,”Says the Lord. 6 This is what the Lord says:“For three offenses of Gaza, and for four,I will not revoke its punishment,Because they led into exile an entire populationTo turn them over to Edom.7 So I will send fire on the wall of GazaAnd it will consume her citadels.8 I will also eliminate every inhabitant from Ashdod,As well as him who holds the scepter, from Ashkelon;And I will direct My power against Ekron,And the remnant of the Philistines will perish,”Says the Lord God. 9 This is what the Lord says:“For three offenses of Tyre, and for four,I will not revoke its punishment,Because they turned an entire population over to EdomAnd did not remember the covenant of brotherhood.10 So I will send fire on the wall of Tyre,And it will consume her citadels.” 11 This is what the Lord says:“For three offenses of Edom, and for four,I will not revoke its punishment,Because he pursued his brother with the swordAnd stifled his compassion;His anger also tore continually,And he maintained his fury forever.12 So I will send fire upon TemanAnd it will consume the citadels of Bozrah.” 13 This is what the Lord says:“For three offenses of the sons of Ammon, and for four,I will not revoke its punishment,Because they ripped open the pregnant women of GileadIn order to enlarge their borders.14 So I will kindle a fire on the wall of Rabbah,And it will consume her citadelsAmid war cries on the day of battle,And amid a storm on the day of tempest.15 Their king will go into exile,He and his princes together,” says the Lord. Chapter 2 1 This is what the Lord says: “For three offenses of Moab, and for four,I will not revoke its punishment,Because he burned the bones of the king of Edom to lime.2 So I will send fire upon MoabAnd it will consume the citadels of Kerioth;And Moab will die amid the panic of battle,Amid war cries and the sound of a trumpet.3 I will also eliminate the judge from her midstAnd slay all her leaders with him,” says the Lord.

In this Bible Story, the great reign of David came to a close. Now Solomon rules over Israel with wisdom, mercy, and justice. As his first act as king, Solomon takes care of those who were loyal to his father, and deals justly with those who betrayed him. This story is inspired by 1 Kings 2. Go to BibleinaYear.com and learn the Bible in a Year.Today's Bible verse is 1 Kings 2:45 from the King James Version.Episode 113: As David is dying, he calls in his son Solomon to bless him and speak God's promises over him. David instructs him on what he should do with Joab and Shimei and requests that he show kindness to Barzillai of Gilead. But Adonijah was not done trying for the throne. He made a request of Bathsheba that Solomon rightly discerned as a claim to the throne. And so as per their agreement, he was executed. Solomon sought to rule his kingdom in fairness and enacted punishments that showed mercy to those who deserved death.Hear the Bible come to life as Pastor Jack Graham leads you through the official BibleinaYear.com podcast. This Biblical Audio Experience will help you master wisdom from the world's greatest book. In each episode, you will learn to apply Biblical principles to everyday life. Now understanding the Bible is easier than ever before; enjoy a cinematic audio experience full of inspirational storytelling, orchestral music, and profound commentary from world-renowned Pastor Jack Graham.Also, you can download the Pray.com app for more Christian content, including, Daily Prayers, Inspirational Testimonies, and Bedtime Bible Stories.Visit JackGraham.org for more resources on how to tap into God's power for successful Christian living.Pray.com is the digital destination of faith. With over 5,000 daily prayers, meditations, bedtime stories, and cinematic stories inspired by the Bible, the Pray.com app has everything you need to keep your focus on the Lord. Make Prayer a priority and download the #1 App for Prayer and Sleep today in the Apple app store or Google Play store.Executive Producers: Steve Gatena & Max BardProducer: Ben GammonHosted by: Pastor Jack GrahamMusic by: Andrew Morgan SmithBible Story narration by: Todd HaberkornSee omnystudio.com/listener for privacy information.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.Jefferies predicts an increase in small tuck-in deals in the biotech industry as companies face challenges accessing capital. Companies and industry groups are offering solutions to mitigate the impact of Trump tariffs on rare disease, cell, and gene therapy. Pitchbook suggests a shift towards more sustainable investing in biotech VC firms. Gilead is gearing up to challenge J&J in the $20 billion multiple myeloma CAR-T market. PTP's generative AI is revolutionizing data summaries for biotech QC workflows. Sanofi recently acquired Blueprint for $9.5 billion, while BMS has committed up to $11 billion with Biontech. Lilly has signed a deal worth up to $870 million, and Regeneron is investing nearly $2 billion in a Chinese obesity drug. Merck's CEO is emphasizing diversity in operations following the defeat of an anti-DEI measure. Immuno-oncology drugs Keytruda and Opdivo may face scrutiny in the near future.In other news, Vigil Neuroscience's Trem2 antibody for a rare brain disease failed in a Phase II trial shortly after Sanofi's acquisition of the company. Analysts believe the results were not surprising and should not impact the deal. Lilly has signed a deal worth up to $870 million to develop a long-acting GLP-1 obesity drug, while the FDA is committed to making rare disease drugs available at the first sign of promise. Pharma tuck-in deals are increasing after a slow first quarter for small biotechs. BioAgc Biologics will be attending Bio International in Boston to discuss their global drug production capabilities.Stay tuned for more updates on investing in research, welcoming global talent, the biotech VC cycle, Gilead's challenge to J&J in the multiple myeloma CAR-T market, and much more. Upcoming events and job listings in the pharmaceutical industry are also featured in our newsletter.Thank you for tuning in to Pharma and Biotech daily.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 609 and 610 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her.              Host: Angelica Monk and Stacey Yvonne Music by: Sammus Edited by: Jamie Broadnax

The words of the week so far in biopharma are “deals” and “cancer”—or, more specifically, money being invested in cancer and other key therapeutic areas. With the American Society of Clinical Oncology's annual conference underway in Chicago, Bristol Myers Squibb got in the PD-1/PD-L1xVEGF game, paying potentially more than $11 billion to co-develop BioNTech's solid tumor bispecific BNT327. Elsewhere, Sanofi nabbed the year's second-biggest buyout, picking up Blueprint for $9.5 billion, expanding its rare disease portfolio. And Regeneron plunked down up to $2 billion to license a dual GLP-1/GIP receptor agonist from Chinese biopharma Hansoh Pharmaceuticals Group.  Back in Chicago, presentations by AstraZeneca, Gilead and Amgen drew rave reviews from investor analysts, while Pfizer and Arvinas elaborated on mixed data from a PROTAC that showed positive results in only a subsection of breast cancer patients, failing to impress Wall Street. Meanwhile, Bicara's solid survival stats in head and neck cancer weren't enough to clear the high bar set by rival Merus. At the meeting, BioSpace's own Dan Samorodnitsky sat down with Jazz Pharmaceuticals' CMO Rob Iannone to discuss the company's recently acquired pediatric glioma drug, and talked AI strategy with AstraZeneca's head of U.S. oncology for lung cancer Arun Krishna. Dan recaps his ASCO experience here.  Speaking of buzzy therapeutic spaces, there was more action on the vaccines front last week as Health and Human Services Secretary RFK Jr. announced that healthy children and healthy pregnant women would no longer be advised to get vaccinated against COVID-19. However, as of publication, the CDC still recommends a COVID vaccine for healthy children but instead of a universal recommendation advises that the decision should be made between parents and healthcare providers. Against this backdrop, the FDA signed off on Moderna's next-gen COVID-19 vaccine, mNEXSPIKE, for a limited population in line with its new guidelines. This was a much-needed win for Moderna, which last week had a $760 million-plus government contract for its mRNA-based bird flu vaccine terminated.  Also on the policy front, the Trump administration released its Make America Healthy Again report last week to much scrutiny after reports found studies and references that did not exist.  

Lez Hang Out is proud to be sponsored by Olivia, the travel company for lesbians and all LGBTQ+ women! Join our Patreon to unlock 25+ full-length bonus episodes (including our brand new one on Bros), ad-free weekly episodes, mp3 downloads of our original songs, exclusive Discord access, and more! Right now, we're retiring our lower tiers– so all new patrons who join at $5/month or higher (or upgrade!) by July 1st, 2025 will be entered into a raffle to guest star on a bonus Patreon episode. You can also support the show by grabbing your #pride gear at bit.ly/lezmerch & picking up Lez-ssentials songs on Bandcamp. Welcome back to Lez Hang Out, the podcast that wants to wish everyone a Happy Pride Month, because queer joy is resistance.  This week, Leigh (@lshfoster) and Ellie (@elliebrigida) hang out with Jennie Wetter, the Director of rePROS Fight Back (@reprosfb), an initiative that fights for sexual and reproductive health rights and justice issues. Jennie is also the creator and host of the rePROs Fight Back podcast. Among the many things that rePROS does to fight back is to grade each of the 50 states on access to reproductive and sexual health rights and care (including access to gender-affirming care). They have recently released their 13th annual (fully interactive!) 50-state Report Card and spoiler alert: The United States as a whole gets an F. Fair warning, looking up your state's grade might make your heart hurt (unless you're like Leigh and live in one of the 5 states that actually got an A).  We talk with Jennie about what things have been like for rePROS since the reversal of Roe and whether our Gilead robes absolutely have to be red (it's just not our color). Although it can be really easy to become overwhelmed by how bad things are, Jennie explains that there's actually a lot to be hopeful about. Between the abortion funds and local clinics there are quite a lot of resources on the ground to help people access care, even in states with strict legislation. Medication abortion remains available and is a fully safe option. With the recent attacks on trans rights, initiatives like rePROS are fighting even harder to ensure access to gender affirming care for all who need it, including minors. Even though at the federal level, things are bleak (that report card is a real eye-opener), there are ways to fight back at the state-level and getting involved locally can really help keep that feeling of doom at bay.  Jennie reminds us that no one person can do or know everything (even if Ellie's ADHD really wants her to try). Figure out which one cause you want to put your energy toward and focus solely on that. Even Jennie doesn't know everything, but she makes herself a trusted resource by knowing what direction to point people in when they come to her for help. Take a deep breath and remember, you don't have to take on everything yourself! Find your lane and follow it and know that others are doing the same in the lanes you didn't choose. Burning yourself out trying to do it all won't help anyone and certainly won't help you feel any better. We see you, we appreciate you, and we want you to remember: no act of resistance is too small.  Give us your own answers to our Q & Gay on Instagram and follow along on Facebook, TikTok, and BlueSky @lezhangoutpod. Find your fav tol and smol hosts Ellie & Leigh at @elliebrigida and @lshfoster. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron's shares have dropped due to the failure of their dupixent follow-up drug, while Sanofi has acquired Blueprint for $9.5 billion to expand their rare disease portfolio. Bristol Myers Squibb is collaborating with Biontech on a bispecific antibody for solid tumors, and Amgen's imdelltra has shown a 40% increase in survival for small cell lung cancer at ASCO. Moderna has received FDA approval for their next-gen COVID-19 vaccine, and AstraZeneca is partnering with AI companies to stop cancer at all stages. Keros has cut 45% of its workforce along with a pulmonary hypertension drug, and Jazz has presented new cancer data at ASCO. FDA actions are pending for companies like Merck, Gilead, and Regeneron/Sanofi.The implications of the overturning of the FDA's lab-developed tests rule in a post-Chevron legal landscape are discussed, where power has shifted from federal agencies to the courts. Upcoming FDA decisions, including Gilead's HIV prophylaxis lenacapavir, are highlighted, along with new FDA guidelines on nitrosamine testing for the pharmaceutical industry. Jazz Pharmaceuticals is in the "goldilocks zone" with new cancer data at ASCO25, showcasing results from acquisitions made over the past five years. Zeiss introduces an AI-powered spatial biology solution for research labs. Other news includes updates from ASCO25, cell and gene therapy developments, and upcoming events in the biopharma industry.

A dying preacher writes a (rather) long letter to his son. Another dying preacher's son returns home, seeking…something. Salvation? Forgiveness? A balm? Robinson's novel is a deeply considered portrait of a family of ministers, wrestling with the powers and limitations of their faith and fatherhood.This episode is sponsored by Squarespace. Go to squarespace.com/overdue for 10% of your first purchase of a website or domain.Our theme music was composed by Nick Lerangis.Follow @overduepod on Instagram and BlueskyAdvertise on OverdueSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jacob escapes with his family, crossing into Gilead while Laban gives chase. When he catches up, accusations fly, but Laban fails to prove that anyone in Jacob's camp stole his household gods. With no evidence and mounting tension, the two men draw a line in the sand—literally—by forging a covenant of peace. This treaty, sealed with a meal and an oath, marks a turning point as Jacob steps further into the promises of God.  Rev. Craig Wehmeyer, pastor of Immanuel Lutheran Church in Washington, MO, joins the Rev. Dr. Phil Booe to study Genesis 31:21-55.  To learn more about Immanuel Lutheran, visit IMLutheran.org. Genesis isn't just the start of the Bible; it's the foundation of everything. Creation, sin, judgment, grace, covenant, and promise all take root in this remarkable book. The stories are ancient, but their truths are eternal. In this new series from Thy Strong Word, Pastor Phil Booe and his guests walk verse by verse through Genesis, exploring how God reveals Himself as Creator, Judge, and Redeemer. From the grandeur of the cosmos to the struggles of ordinary families, Genesis introduces us to a God who speaks, acts, and keeps His promises. So, whether you've read it a hundred times or are just now cracking it open for a serious look, this series will help you see Genesis with fresh eyes—and a deeper faith. Thy Strong Word, hosted by Rev. Dr. Phil Booe, pastor of St. John Lutheran Church of Luverne, MN, reveals the light of our salvation in Christ through study of God's Word, breaking our darkness with His redeeming light. Each weekday, two pastors fix our eyes on Jesus by considering Holy Scripture, verse by verse, in order to be strengthened in the Word and be equipped to faithfully serve in our daily vocations. Submit comments or questions to: thystrongword@kfuo.org.

Obadiah 1:1-21 The vision of Obadiah. Thus says the Lord God concerning Edom: We have heard a report from the Lord, and a messenger has been sent among the nations: “Rise up! Let us rise against her for battle!” 2 Behold, I will make you small among the nations; you shall be utterly despised. 3 The pride of your heart has deceived you, you who live in the clefts of the rock, in your lofty dwelling, who say in your heart, “Who will bring me down to the ground?” 4 Though you soar aloft like the eagle, though your nest is set among the stars, from there I will bring you down, declares the Lord. 5 If thieves came to you, if plunderers came by night— how you have been destroyed!— would they not steal only enough for themselves? If grape gatherers came to you, would they not leave gleanings? 6 How Esau has been pillaged, his treasures sought out! 7 All your allies have driven you to your border; those at peace with you have deceived you; they have prevailed against you; those who eat your bread have set a trap beneath you— you have no understanding. 8 Will I not on that day, declares the Lord, destroy the wise men out of Edom, and understanding out of Mount Esau? 9 And your mighty men shall be dis-mayed, O Teman, so that every man from Mount Esau will be cut off by slaughter. 10 Because of the violence done to your brother Jacob, shame shall cover you, and you shall be cut off forever. 11 On the day that you stood aloof, on the day that strangers carried off his wealth and foreigners entered his gates and cast lots for Jerusalem, you were like one of them. 12 But do not gloat over the day of your brother in the day of his misfortune; do not rejoice over the people of Judah in the day of their ruin; do not boast in the day of distress. 13 Do not enter the gate of my people in the day of their calamity; do not gloat over his disaster in the day of his calamity; do not loot his wealth in the day of his calamity. 14 Do not stand at the crossroads to cut off his fugitives; do not hand over his survivors in the day of distress. 15 For the day of the Lord is near upon all the nations. As you have done, it shall be done to you; your deeds shall return on your own head. 16 For as you have drunk on my holy mountain, so all the nations shall drink continually; they shall drink and swallow, and shall be as though they had never been. 17 But in Mount Zion there shall be those who escape, and it shall be holy, and the house of Jacob shall possess their own possessions. 18 The house of Jacob shall be a fire, and the house of Joseph a flame, and the house of Esau stubble; they shall burn them and consume them, and there shall be no survivor for the house of Esau, for the Lord has spoken. 19 Those of the Negeb shall possess Mount Esau, and those of the Shephelah shall possess the land of the Philistines; they shall possess the land of Ephraim and the land of Samaria, and Benjamin shall possess Gilead. 20 The exiles of this host of the people of Israel shall possess the land of the Canaanites as far as Zarephath, and the exiles of Jerusalem who are in Sepharad shall possess the cities of the Negeb. 21 Saviors shall go up to Mount Zion to rule Mount Esau, and the kingdom shall be the Lord's.

E9 - Execution. June faces her biggest challenge as Gilead cracks down on the rebels.E10 - The Handmaid's Tale. June reflects on her experiences in Gilead and decides what to do next.Join Brittany and Amber of @OllivAmbersWands as we discuss the penultimate and series finale of Margaret Atwood's novel, The Handmaid's Tale. #TheHandmaidsTale #PraiseBeThe Handmaid's Tale (2017) is the Hulu Original series starring Elisabeth Moss, Yvonne Strahovski, Ann Dowd, Madeline Brewer, Max Minghella, O-T Fagbenle, and Bradley Whitford.Subscribe to OllivAmber's Wands:https://www.youtube.com/channel/UC5utepPfYkwxaG7ph5CcgiAFollow OllivAmber's Wands on Instagram:https://www.instagram.com/ollivambers.wands/Subscribe, rate and review! Follow The Watchers in the Basement on social media! Use #WatchersBasement to comment about the show!facebook.com/watchersbasementtwitter.com/WatchBasement instagram.com/watchersbasementthreads.net/@watchersbasementanchor.fm/watchersbasement

April 26, 2025 - Equipped 2025 - Day 3 - 9:00AM Session   Richard leads a bible study Isaiah 3, 13, 53 and other passages which point as what an effective shepherd would look like. From a foundation of believes to actions, Richard explains and provides examples of shepherds.   2 Kings 15-21 - Azariah Reigns in Judah 15 In the twenty-seventh year of Jeroboam king of Israel, Azariah the son of Amaziah, king of Judah, became king. 2 He was sixteen years old when he became king, and he reigned fifty-two years in Jerusalem. His mother's name was Jecholiah of Jerusalem. 3 And he did what was right in the sight of the Lord, according to all that his father Amaziah had done, 4 except that the high places were not removed; the people still sacrificed and burned incense on the high places. 5 Then the Lord struck the king, so that he was a leper until the day of his death; so he dwelt in an isolated house. And Jotham the king's son was over the royal house, judging the people of the land. 6 Now the rest of the acts of Azariah, and all that he did, are they not written in the book of the chronicles of the kings of Judah? 7 So Azariah rested with his fathers, and they buried him with his fathers in the City of David. Then Jotham his son reigned in his place. Zechariah Reigns in Israel 8 In the thirty-eighth year of Azariah king of Judah, Zechariah the son of Jeroboam reigned over Israel in Samaria six months. 9 And he did evil in the sight of the Lord, as his fathers had done; he did not depart from the sins of Jeroboam the son of Nebat, who had made Israel sin. 10 Then Shallum the son of Jabesh conspired against him, and struck and killed him in front of the people; and he reigned in his place. 11 Now the rest of the acts of Zechariah, indeed they are written in the book of the chronicles of the kings of Israel. 12 This was the word of the Lord which He spoke to Jehu, saying, “Your sons shall sit on the throne of Israel to the fourth generation.” And so it was. Shallum Reigns in Israel 13 Shallum the son of Jabesh became king in the thirty-ninth year of Uzziah king of Judah; and he reigned a full month in Samaria. 14 For Menahem the son of Gadi went up from Tirzah, came to Samaria, and struck Shallum the son of Jabesh in Samaria and killed him; and he reigned in his place. 15 Now the rest of the acts of Shallum, and the conspiracy which he led, indeed they are written in the book of the chronicles of the kings of Israel. 16 Then from Tirzah, Menahem attacked Tiphsah, all who were there, and its territory. Because they did not surrender, therefore he attacked it. All the women there who were with child he ripped open. Menahem Reigns in Israel 17 In the thirty-ninth year of Azariah king of Judah, Menahem the son of Gadi became king over Israel, and reigned ten years in Samaria. 18 And he did evil in the sight of the Lord; he did not depart all his days from the sins of Jeroboam the son of Nebat, who had made Israel sin. 19 Pul king of Assyria came against the land; and Menahem gave Pul a thousand talents of silver, that his hand might be with him to strengthen the kingdom under his control. 20 And Menahem exacted the money from Israel, from all the very wealthy, from each man fifty shekels of silver, to give to the king of Assyria. So the king of Assyria turned back, and did not stay there in the land. 21 Now the rest of the acts of Menahem, and all that he did, are they not written in the book of the chronicles of the kings of Israel? 22 So Menahem rested with his fathers. Then Pekahiah his son reigned in his place. Pekahiah Reigns in Israel 23 In the fiftieth year of Azariah king of Judah, Pekahiah the son of Menahem became king over Israel in Samaria, and reigned two years. 24 And he did evil in the sight of the Lord; he did not depart from the sins of Jeroboam the son of Nebat, who had made Israel sin. 25 Then Pekah the son of Remaliah, an officer of his, conspired against him and killed him in Samaria, in the citadel of the king's house, along with Argob and Arieh; and with him were fifty men of Gilead. He killed him and reigned in his place. 26 Now the rest of the acts of Pekahiah, and all that he did, indeed they are written in the book of the chronicles of the kings of Israel. Pekah Reigns in Israel 27 In the fifty-second year of Azariah king of Judah, Pekah the son of Remaliah became king over Israel in Samaria, and reigned twenty years. 28 And he did evil in the sight of the Lord; he did not depart from the sins of Jeroboam the son of Nebat, who had made Israel sin. 29 In the days of Pekah king of Israel, Tiglath-Pileser king of Assyria came and took Ijon, Abel Beth Maachah, Janoah, Kedesh, Hazor, Gilead, and Galilee, all the land of Naphtali; and he carried them captive to Assyria. 30 Then Hoshea the son of Elah led a conspiracy against Pekah the son of Remaliah, and struck and killed him; so he reigned in his place in the twentieth year of Jotham the son of Uzziah. 31 Now the rest of the acts of Pekah, and all that he did, indeed they are written in the book of the chronicles of the kings of Israel. Jotham Reigns in Judah 32 In the second year of Pekah the son of Remaliah, king of Israel, Jotham the son of Uzziah, king of Judah, began to reign. 33 He was twenty-five years old when he became king, and he reigned sixteen years in Jerusalem. His mother's name was Jerusha the daughter of Zadok. 34 And he did what was right in the sight of the Lord; he did according to all that his father Uzziah had done. 35 However the high places were not removed; the people still sacrificed and burned incense on the high places. He built the Upper Gate of the house of the Lord. 36 Now the rest of the acts of Jotham, and all that he did, are they not written in the book of the chronicles of the kings of Judah? 37 In those days the Lord began to send Rezin king of Syria and Pekah the son of Remaliah against Judah. 38 So Jotham rested with his fathers, and was buried with his fathers in the City of David his father. Then Ahaz his son reigned in his place. Ahaz Reigns in Judah 16 In the seventeenth year of Pekah the son of Remaliah, Ahaz the son of Jotham, king of Judah, began to reign. 2 Ahaz was twenty years old when he became king, and he reigned sixteen years in Jerusalem; and he did not do what was right in the sight of the Lord his God, as his father David had done. 3 But he walked in the way of the kings of Israel; indeed he made his son pass through the fire, according to the abominations of the nations whom the Lord had cast out from before the children of Israel. 4 And he sacrificed and burned incense on the high places, on the hills, and under every green tree. 5 Then Rezin king of Syria and Pekah the son of Remaliah, king of Israel, came up to Jerusalem to make war; and they besieged Ahaz but could not overcome him. 6 At that time Rezin king of Syria captured Elath for Syria, and drove the men of Judah from Elath. Then the Edomites went to Elath, and dwell there to this day. 7 So Ahaz sent messengers to Tiglath-Pileser king of Assyria, saying, “I am your servant and your son. Come up and save me from the hand of the king of Syria and from the hand of the king of Israel, who rise up against me.” 8 And Ahaz took the silver and gold that was found in the house of the Lord, and in the treasuries of the king's house, and sent it as a present to the king of Assyria. 9 So the king of Assyria heeded him; for the king of Assyria went up against Damascus and took it, carried its people captive to Kir, and killed Rezin. 10 Now King Ahaz went to Damascus to meet Tiglath-Pileser king of Assyria, and saw an altar that was at Damascus; and King Ahaz sent to Urijah the priest the design of the altar and its pattern, according to all its workmanship. 11 Then Urijah the priest built an altar according to all that King Ahaz had sent from Damascus. So Urijah the priest made it before King Ahaz came back from Damascus. 12 And when the king came back from Damascus, the king saw the altar; and the king approached the altar and made offerings on it. 13 So he burned his burnt offering and his grain offering; and he poured his drink offering and sprinkled the blood of his peace offerings on the altar. 14 He also brought the bronze altar which was before the Lord, from the front of the temple—from between the new altar and the house of the Lord—and put it on the north side of the new altar. 15 Then King Ahaz commanded Urijah the priest, saying, “On the great new altar burn the morning burnt offering, the evening grain offering, the king's burnt sacrifice, and his grain offering, with the burnt offering of all the people of the land, their grain offering, and their drink offerings; and sprinkle on it all the blood of the burnt offering and all the blood of the sacrifice. And the bronze altar shall be for me to inquire by.” 16 Thus did Urijah the priest, according to all that King Ahaz commanded. 17 And King Ahaz cut off the panels of the carts, and removed the lavers from them; and he took down the Sea from the bronze oxen that were under it, and put it on a pavement of stones. 18 Also he removed the Sabbath pavilion which they had built in the temple, and he removed the king's outer entrance from the house of the Lord, on account of the king of Assyria. 19 Now the rest of the acts of Ahaz which he did, are they not written in the book of the chronicles of the kings of Judah? 20 So Ahaz rested with his fathers, and was buried with his fathers in the City of David. Then Hezekiah his son reigned in his place. Hoshea Reigns in Israel 17 In the twelfth year of Ahaz king of Judah, Hoshea the son of Elah became king of Israel in Samaria, and he reigned nine years. 2 And he did evil in the sight of the Lord, but not as the kings of Israel who were before him. 3 Shalmaneser king of Assyria came up against him; and Hoshea became his vassal, and paid him tribute money. 4 And the king of Assyria uncovered a conspiracy by Hoshea; for he had sent messengers to So, king of Egypt, and brought no tribute to the king of Assyria, as he had done year by year. Therefore the king of Assyria shut him up, and bound him in prison. Israel Carried Captive to Assyria 5 Now the king of Assyria went throughout all the land, and went up to Samaria and besieged it for three years. 6 In the ninth year of Hoshea, the king of Assyria took Samaria and carried Israel away to Assyria, and placed them in Halah and by the Habor, the River of Gozan, and in the cities of the Medes. 7 For so it was that the children of Israel had sinned against the Lord their God, who had brought them up out of the land of Egypt, from under the hand of Pharaoh king of Egypt; and they had feared other gods, 8 and had walked in the statutes of the nations whom the Lord had cast out from before the children of Israel, and of the kings of Israel, which they had made. 9 Also the children of Israel secretly did against the Lord their God things that were not right, and they built for themselves high places in all their cities, from watchtower to fortified city. 10 They set up for themselves sacred pillars and wooden images on every high hill and under every green tree. 11 There they burned incense on all the high places, like the nations whom the Lord had carried away before them; and they did wicked things to provoke the Lord to anger, 12 for they served idols, of which the Lord had said to them, “You shall not do this thing.” 13 Yet the Lord testified against Israel and against Judah, by all of His prophets, every seer, saying, “Turn from your evil ways, and keep My commandments and My statutes, according to all the law which I commanded your fathers, and which I sent to you by My servants the prophets.” 14 Nevertheless they would not hear, but stiffened their necks, like the necks of their fathers, who did not believe in the Lord their God. 15 And they rejected His statutes and His covenant that He had made with their fathers, and His testimonies which He had testified against them; they followed idols, became idolaters, and went after the nations who were all around them, concerning whom the Lord had charged them that they should not do like them. 16 So they left all the commandments of the Lord their God, made for themselves a molded image and two calves, made a wooden image and worshiped all the host of heaven, and served Baal. 17 And they caused their sons and daughters to pass through the fire, practiced witchcraft and soothsaying, and sold themselves to do evil in the sight of the Lord, to provoke Him to anger. 18 Therefore the Lord was very angry with Israel, and removed them from His sight; there was none left but the tribe of Judah alone. 19 Also Judah did not keep the commandments of the Lord their God, but walked in the statutes of Israel which they made. 20 And the Lord rejected all the descendants of Israel, afflicted them, and delivered them into the hand of plunderers, until He had cast them from His sight. 21 For He tore Israel from the house of David, and they made Jeroboam the son of Nebat king. Then Jeroboam drove Israel from following the Lord, and made them commit a great sin. 22 For the children of Israel walked in all the sins of Jeroboam which he did; they did not depart from them, 23 until the Lord removed Israel out of His sight, as He had said by all His servants the prophets. So Israel was carried away from their own land to Assyria, as it is to this day. Assyria Resettles Samaria 24 Then the king of Assyria brought people from Babylon, Cuthah, Ava, Hamath, and from Sepharvaim, and placed them in the cities of Samaria instead of the children of Israel; and they took possession of Samaria and dwelt in its cities. 25 And it was so, at the beginning of their dwelling there, that they did not fear the Lord; therefore the Lord sent lions among them, which killed some of them. 26 So they spoke to the king of Assyria, saying, “The nations whom you have removed and placed in the cities of Samaria do not know the rituals of the God of the land; therefore He has sent lions among them, and indeed, they are killing them because they do not know the rituals of the God of the land.” 27 Then the king of Assyria commanded, saying, “Send there one of the priests whom you brought from there; let him go and dwell there, and let him teach them the rituals of the God of the land.” 28 Then one of the priests whom they had carried away from Samaria came and dwelt in Bethel, and taught them how they should fear the Lord. 29 However every nation continued to make gods of its own, and put them in the shrines on the high places which the Samaritans had made, every nation in the cities where they dwelt. 30 The men of Babylon made Succoth Benoth, the men of Cuth made Nergal, the men of Hamath made Ashima, 31 and the Avites made Nibhaz and Tartak; and the Sepharvites burned their children in fire to Adrammelech and Anammelech, the gods of Sepharvaim. 32 So they feared the Lord, and from every class they appointed for themselves priests of the high places, who sacrificed for them in the shrines of the high places. 33 They feared the Lord, yet served their own gods—according to the rituals of the nations from among whom they were carried away. 34 To this day they continue practicing the former rituals; they do not fear the Lord, nor do they follow their statutes or their ordinances, or the law and commandment which the Lord had commanded the children of Jacob, whom He named Israel, 35 with whom the Lord had made a covenant and charged them, saying: “You shall not fear other gods, nor bow down to them nor serve them nor sacrifice to them; 36 but the Lord, who brought you up from the land of Egypt with great power and an outstretched arm, Him you shall fear, Him you shall worship, and to Him you shall offer sacrifice. 37 And the statutes, the ordinances, the law, and the commandment which He wrote for you, you shall be careful to observe forever; you shall not fear other gods. 38 And the covenant that I have made with you, you shall not forget, nor shall you fear other gods. 39 But the Lord your God you shall fear; and He will deliver you from the hand of all your enemies.” 40 However they did not obey, but they followed their former rituals. 41 So these nations feared the Lord, yet served their carved images; also their children and their children's children have continued doing as their fathers did, even to this day. Hezekiah Reigns in Judah 18 Now it came to pass in the third year of Hoshea the son of Elah, king of Israel, that Hezekiah the son of Ahaz, king of Judah, began to reign. 2 He was twenty-five years old when he became king, and he reigned twenty-nine years in Jerusalem. His mother's name was Abi the daughter of Zechariah. 3 And he did what was right in the sight of the Lord, according to all that his father David had done. 4 He removed the high places and broke the sacred pillars, cut down the wooden image and broke in pieces the bronze serpent that Moses had made; for until those days the children of Israel burned incense to it, and called it Nehushtan. 5 He trusted in the Lord God of Israel, so that after him was none like him among all the kings of Judah, nor who were before him. 6 For he held fast to the Lord; he did not depart from following Him, but kept His commandments, which the Lord had commanded Moses. 7 The Lord was with him; he prospered wherever he went. And he rebelled against the king of Assyria and did not serve him. 8 He subdued the Philistines, as far as Gaza and its territory, from watchtower to fortified city. 9 Now it came to pass in the fourth year of King Hezekiah, which was the seventh year of Hoshea the son of Elah, king of Israel, that Shalmaneser king of Assyria came up against Samaria and besieged it. 10 And at the end of three years they took it. In the sixth year of Hezekiah, that is, the ninth year of Hoshea king of Israel, Samaria was taken. 11 Then the king of Assyria carried Israel away captive to Assyria, and put them in Halah and by the Habor, the River of Gozan, and in the cities of the Medes, 12 because they did not obey the voice of the Lord their God, but transgressed His covenant and all that Moses the servant of the Lord had commanded; and they would neither hear nor do them. 13 And in the fourteenth year of King Hezekiah, Sennacherib king of Assyria came up against all the fortified cities of Judah and took them. 14 Then Hezekiah king of Judah sent to the king of Assyria at Lachish, saying, “I have done wrong; turn away from me; whatever you impose on me I will pay.” And the king of Assyria assessed Hezekiah king of Judah three hundred talents of silver and thirty talents of gold. 15 So Hezekiah gave him all the silver that was found in the house of the Lord and in the treasuries of the king's house. 16 At that time Hezekiah stripped the gold from the doors of the temple of the Lord, and from the pillars which Hezekiah king of Judah had overlaid, and gave it to the king of Assyria. Sennacherib Boasts Against the Lord 17 Then the king of Assyria sent the Tartan, the Rabsaris, and the Rabshakeh from Lachish, with a great army against Jerusalem, to King Hezekiah. And they went up and came to Jerusalem. When they had come up, they went and stood by the aqueduct from the upper pool, which was on the highway to the Fuller's Field. 18 And when they had called to the king, Eliakim the son of Hilkiah, who was over the household, Shebna the scribe, and Joah the son of Asaph, the recorder, came out to them. 19 Then the Rabshakeh said to them, “Say now to Hezekiah, ‘Thus says the great king, the king of Assyria: “What confidence is this in which you trust? 20 You speak of having plans and power for war; but they are mere words. And in whom do you trust, that you rebel against me? 21 Now look! You are trusting in the staff of this broken reed, Egypt, on which if a man leans, it will go into his hand and pierce it. So is Pharaoh king of Egypt to all who trust in him. 22 But if you say to me, ‘We trust in the Lord our God,' is it not He whose high places and whose altars Hezekiah has taken away, and said to Judah and Jerusalem, ‘You shall worship before this altar in Jerusalem'?” ' 23 Now therefore, I urge you, give a pledge to my master the king of Assyria, and I will give you two thousand horses—if you are able on your part to put riders on them! 24 How then will you repel one captain of the least of my master's servants, and put your trust in Egypt for chariots and horsemen? 25 Have I now come up without the Lord against this place to destroy it? The Lord said to me, ‘Go up against this land, and destroy it.' ” 26 Then Eliakim the son of Hilkiah, Shebna, and Joah said to the Rabshakeh, “Please speak to your servants in Aramaic, for we understand it; and do not speak to us in Hebrew in the hearing of the people who are on the wall.” 27 But the Rabshakeh said to them, “Has my master sent me to your master and to you to speak these words, and not to the men who sit on the wall, who will eat and drink their own waste with you?” 28 Then the Rabshakeh stood and called out with a loud voice in Hebrew, and spoke, saying, “Hear the word of the great king, the king of Assyria! 29 Thus says the king: ‘Do not let Hezekiah deceive you, for he shall not be able to deliver you from his hand; 30 nor let Hezekiah make you trust in the Lord, saying, “The Lord will surely deliver us; this city shall not be given into the hand of the king of Assyria.” ' 31 Do not listen to Hezekiah; for thus says the king of Assyria: ‘Make peace with me by a present and come out to me; and every one of you eat from his own vine and every one from his own fig tree, and every one of you drink the waters of his own cistern; 32 until I come and take you away to a land like your own land, a land of grain and new wine, a land of bread and vineyards, a land of olive groves and honey, that you may live and not die. But do not listen to Hezekiah, lest he persuade you, saying, “The Lord will deliver us.” 33 Has any of the gods of the nations at all delivered its land from the hand of the king of Assyria? 34 Where are the gods of Hamath and Arpad? Where are the gods of Sepharvaim and Hena and Ivah? Indeed, have they delivered Samaria from my hand? 35 Who among all the gods of the lands have delivered their countries from my hand, that the Lord should deliver Jerusalem from my hand?' ” 36 But the people held their peace and answered him not a word; for the king's commandment was, “Do not answer him.” 37 Then Eliakim the son of Hilkiah, who was over the household, Shebna the scribe, and Joah the son of Asaph, the recorder, came to Hezekiah with their clothes torn, and told him the words of the Rabshakeh. Isaiah Assures Deliverance 19 And so it was, when King Hezekiah heard it, that he tore his clothes, covered himself with sackcloth, and went into the house of the Lord. 2 Then he sent Eliakim, who was over the household, Shebna the scribe, and the elders of the priests, covered with sackcloth, to Isaiah the prophet, the son of Amoz. 3 And they said to him, “Thus says Hezekiah: ‘This day is a day of trouble, and rebuke, and blasphemy; for the children have come to birth, but there is no strength to bring them forth. 4 It may be that the Lord your God will hear all the words of the Rabshakeh, whom his master the king of Assyria has sent to reproach the living God, and will rebuke the words which the Lord your God has heard. Therefore lift up your prayer for the remnant that is left.' ” 5 So the servants of King Hezekiah came to Isaiah. 6 And Isaiah said to them, “Thus you shall say to your master, ‘Thus says the Lord: “Do not be afraid of the words which you have heard, with which the servants of the king of Assyria have blasphemed Me. 7 Surely I will send a spirit upon him, and he shall hear a rumor and return to his own land; and I will cause him to fall by the sword in his own land.” ' ” Sennacherib's Threat and Hezekiah's Prayer 8 Then the Rabshakeh returned and found the king of Assyria warring against Libnah, for he heard that he had departed from Lachish. 9 And the king heard concerning Tirhakah king of Ethiopia, “Look, he has come out to make war with you.” So he again sent messengers to Hezekiah, saying, 10 “Thus you shall speak to Hezekiah king of Judah, saying: ‘Do not let your God in whom you trust deceive you, saying, “Jerusalem shall not be given into the hand of the king of Assyria.” 11 Look! You have heard what the kings of Assyria have done to all lands by utterly destroying them; and shall you be delivered? 12 Have the gods of the nations delivered those whom my fathers have destroyed, Gozan and Haran and Rezeph, and the people of Eden who were in Telassar? 13 Where is the king of Hamath, the king of Arpad, and the king of the city of Sepharvaim, Hena, and Ivah?' ” 14 And Hezekiah received the letter from the hand of the messengers, and read it; and Hezekiah went up to the house of the Lord, and spread it before the Lord. 15 Then Hezekiah prayed before the Lord, and said: “O Lord God of Israel, the One who dwells between the cherubim, You are God, You alone, of all the kingdoms of the earth. You have made heaven and earth. 16 Incline Your ear, O Lord, and hear; open Your eyes, O Lord, and see; and hear the words of Sennacherib, which he has sent to reproach the living God. 17 Truly, Lord, the kings of Assyria have laid waste the nations and their lands, 18 and have cast their gods into the fire; for they were not gods, but the work of men's hands—wood and stone. Therefore they destroyed them. 19 Now therefore, O Lord our God, I pray, save us from his hand, that all the kingdoms of the earth may know that You are the Lord God, You alone.” The Word of the Lord Concerning Sennacherib 20 Then Isaiah the son of Amoz sent to Hezekiah, saying, “Thus says the Lord God of Israel: ‘Because you have prayed to Me against Sennacherib king of Assyria, I have heard.' 21 This is the word which the Lord has spoken concerning him: ‘The virgin, the daughter of Zion, Has despised you, laughed you to scorn; The daughter of Jerusalem Has shaken her head behind your back! 22 ‘Whom have you reproached and blasphemed? Against whom have you raised your voice, And lifted up your eyes on high? Against the Holy One of Israel. 23 By your messengers you have reproached the Lord, And said: “By the multitude of my chariots I have come up to the height of the mountains, To the limits of Lebanon; I will cut down its tall cedars And its choice cypress trees; I will enter the extremity of its borders, To its fruitful forest. 24 I have dug and drunk strange water, And with the soles of my feet I have dried up All the brooks of defense.” 25 ‘Did you not hear long ago How I made it, From ancient times that I formed it? Now I have brought it to pass, That you should be For crushing fortified cities into heaps of ruins. 26 Therefore their inhabitants had little power; They were dismayed and confounded; They were as the grass of the field And the green herb, As the grass on the housetops And grain blighted before it is grown. 27 ‘But I know your dwelling place, Your going out and your coming in, And your rage against Me. 28 Because your rage against Me and your tumult Have come up to My ears, Therefore I will put My hook in your nose And My bridle in your lips, And I will turn you back By the way which you came. 29 ‘This shall be a sign to you: ‘You shall eat this year such as grows of itself, And in the second year what springs from the same; Also in the third year sow and reap, Plant vineyards and eat the fruit of them. 30 And the remnant who have escaped of the house of Judah Shall again take root downward, And bear fruit upward. 31 For out of Jerusalem shall go a remnant, And those who escape from Mount Zion. The zeal of the Lord of hosts will do this.' 32 “Therefore thus says the Lord concerning the king of Assyria: ‘He shall not come into this city, Nor shoot an arrow there, Nor come before it with shield, Nor build a siege mound against it. 33 By the way that he came, By the same shall he return; And he shall not come into this city,' Says the Lord. 34 ‘For I will defend this city, to save it For My own sake and for My servant David's sake.' ” Sennacherib's Defeat and Death 35 And it came to pass on a certain night that the angel of the Lord went out, and killed in the camp of the Assyrians one hundred and eighty-five thousand; and when people arose early in the morning, there were the corpses—all dead. 36 So Sennacherib king of Assyria departed and went away, returned home, and remained at Nineveh. 37 Now it came to pass, as he was worshiping in the temple of Nisroch his god, that his sons Adrammelech and Sharezer struck him down with the sword; and they escaped into the land of Ararat. Then Esarhaddon his son reigned in his place. Hezekiah's Life Extended 20 In those days Hezekiah was sick and near death. And Isaiah the prophet, the son of Amoz, went to him and said to him, “Thus says the Lord: ‘Set your house in order, for you shall die, and not live.' ” 2 Then he turned his face toward the wall, and prayed to the Lord, saying, 3 “Remember now, O Lord, I pray, how I have walked before You in truth and with a loyal heart, and have done what was good in Your sight.” And Hezekiah wept bitterly. 4 And it happened, before Isaiah had gone out into the middle court, that the word of the Lord came to him, saying, 5 “Return and tell Hezekiah the leader of My people, ‘Thus says the Lord, the God of David your father: “I have heard your prayer, I have seen your tears; surely I will heal you. On the third day you shall go up to the house of the Lord. 6 And I will add to your days fifteen years. I will deliver you and this city from the hand of the king of Assyria; and I will defend this city for My own sake, and for the sake of My servant David.” ' ” 7 Then Isaiah said, “Take a lump of figs.” So they took and laid it on the boil, and he recovered. 8 And Hezekiah said to Isaiah, “What is the sign that the Lord will heal me, and that I shall go up to the house of the Lord the third day?” 9 Then Isaiah said, “This is the sign to you from the Lord, that the Lord will do the thing which He has spoken: shall the shadow go forward ten degrees or go backward ten degrees?” 10 And Hezekiah answered, “It is an easy thing for the shadow to go down ten degrees; no, but let the shadow go backward ten degrees.” 11 So Isaiah the prophet cried out to the Lord, and He brought the shadow ten degrees backward, by which it had gone down on the sundial of Ahaz. The Babylonian Envoys 12 At that time Berodach-Baladan the son of Baladan, king of Babylon, sent letters and a present to Hezekiah, for he heard that Hezekiah had been sick. 13 And Hezekiah was attentive to them, and showed them all the house of his treasures—the silver and gold, the spices and precious ointment, and all his armory—all that was found among his treasures. There was nothing in his house or in all his dominion that Hezekiah did not show them. 14 Then Isaiah the prophet went to King Hezekiah, and said to him, “What did these men say, and from where did they come to you?” So Hezekiah said, “They came from a far country, from Babylon.” 15 And he said, “What have they seen in your house?” So Hezekiah answered, “They have seen all that is in my house; there is nothing among my treasures that I have not shown them.” 16 Then Isaiah said to Hezekiah, “Hear the word of the Lord: 17 ‘Behold, the days are coming when all that is in your house, and what your fathers have accumulated until this day, shall be carried to Babylon; nothing shall be left,' says the Lord. 18 ‘And they shall take away some of your sons who will descend from you, whom you will beget; and they shall be eunuchs in the palace of the king of Babylon.' ” 19 So Hezekiah said to Isaiah, “The word of the Lord which you have spoken is good!” For he said, “Will there not be peace and truth at least in my days?” Death of Hezekiah 20 Now the rest of the acts of Hezekiah—all his might, and how he made a pool and a tunnel and brought water into the city—are they not written in the book of the chronicles of the kings of Judah? 21 So Hezekiah rested with his fathers. Then Manasseh his son reigned in his place. Manasseh Reigns in Judah 21 Manasseh was twelve years old when he became king, and he reigned fifty-five years in Jerusalem. His mother's name was Hephzibah. 2 And he did evil in the sight of the Lord, according to the abominations of the nations whom the Lord had cast out before the children of Israel. 3 For he rebuilt the high places which Hezekiah his father had destroyed; he raised up altars for Baal, and made a wooden image, as Ahab king of Israel had done; and he worshiped all the host of heaven and served them. 4 He also built altars in the house of the Lord, of which the Lord had said, “In Jerusalem I will put My name.” 5 And he built altars for all the host of heaven in the two courts of the house of the Lord. 6 Also he made his son pass through the fire, practiced soothsaying, used witchcraft, and consulted spiritists and mediums. He did much evil in the sight of the Lord, to provoke Him to anger. 7 He even set a carved image of Asherah that he had made, in the house of which the Lord had said to David and to Solomon his son, “In this house and in Jerusalem, which I have chosen out of all the tribes of Israel, I will put My name forever; 8 and I will not make the feet of Israel wander anymore from the land which I gave their fathers—only if they are careful to do according to all that I have commanded them, and according to all the law that My servant Moses commanded them.” 9 But they paid no attention, and Manasseh seduced them to do more evil than the nations whom the Lord had destroyed before the children of Israel. 10 And the Lord spoke by His servants the prophets, saying, 11 “Because Manasseh king of Judah has done these abominations (he has acted more wickedly than all the Amorites who were before him, and has also made Judah sin with his idols), 12 therefore thus says the Lord God of Israel: ‘Behold, I am bringing such calamity upon Jerusalem and Judah, that whoever hears of it, both his ears will tingle. 13 And I will stretch over Jerusalem the measuring line of Samaria and the plummet of the house of Ahab; I will wipe Jerusalem as one wipes a dish, wiping it and turning it upside down. 14 So I will forsake the remnant of My inheritance and deliver them into the hand of their enemies; and they shall become victims of plunder to all their enemies, 15 because they have done evil in My sight, and have provoked Me to anger since the day their fathers came out of Egypt, even to this day.' ” 16 Moreover Manasseh shed very much innocent blood, till he had filled Jerusalem from one end to another, besides his sin by which he made Judah sin, in doing evil in the sight of the Lord. 17 Now the rest of the acts of Manasseh—all that he did, and the sin that he committed—are they not written in the book of the chronicles of the kings of Judah? 18 So Manasseh rested with his fathers, and was buried in the garden of his own house, in the garden of Uzza. Then his son Amon reigned in his place. Amon's Reign and Death 19 Amon was twenty-two years old when he became king, and he reigned two years in Jerusalem. His mother's name was Meshullemeth the daughter of Haruz of Jotbah. 20 And he did evil in the sight of the Lord, as his father Manasseh had done. 21 So he walked in all the ways that his father had walked; and he served the idols that his father had served, and worshiped them. 22 He forsook the Lord God of his fathers, and did not walk in the way of the Lord. 23 Then the servants of Amon conspired against him, and killed the king in his own house. 24 But the people of the land executed all those who had conspired against King Amon. Then the people of the land made his son Josiah king in his place. 25 Now the rest of the acts of Amon which he did, are they not written in the book of the chronicles of the kings of Judah? 26 And he was buried in his tomb in the garden of Uzza. Then Josiah his son reigned in his place.       Video: https://www.youtube.com/watch?v=KYpEm7AL4fU   Duration 40:15

In this podcast episode the Ohio Field Leader Roadshow made a stop in Morrow County at the farm of Ray Van Horn. Dusty and Ray discuss the current planting season, and unique aspects of farming some of the gently rolling clay soils around Mt. Gilead. They also discuss the important role of agricultural commodity organizations and the value of building relationships to foster trade around the world from a combine seat in Ohio.

The fall of Gilead!

“And the men of Judah came, and there they anointed David king over the house of Judah. When they told David, “It was the men of Jabesh-gilead who buried Saul,” David sent messengers to the men of Jabesh-gilead and said to them, “May you be blessed by the Lord, because you showed this loyalty to Saul your Lord and buried him. Now may the Lord show steadfast love and faithfulness to you. And I will do good to you because you have done this thing. Now therefore let your hands be strong, and be valiant, for Saul your Lord is dead, and the house of Judah has anointed me king over them.” But Abner the son of Ner, commander of Saul's army, took Ish-bosheth the son of Saul and brought him over to Mahanaim, and he made him king over Gilead and the Ashurites and Jezreel and Ephraim and Benjamin and all Israel.” - 2 Samuel‬ ‭2‬:‭4‬-‭9‬ ‭ESV‬

In a world competing for our attention, our guest this week admits: “It's probably harder to read novels now than it ever was.” But their value cannot be overstated. The novel's unique humanity, its careful and open treatment of the human experience, helps us to develop a sympathetic imagination, tuning our hearts and minds in a way that non-fiction argument simply cannot. Christopher Scalia, author of 13 Novels Conservatives Will Love (but Probably Haven't Read), makes the case that it is a distinctly conservative interest to explore the Western tradition through fiction. Recommendations in hand, he invites adults to refresh their reading list with novels—from the very inception of the form up to the present. Chapters: 1:47 The great book rut 4:11 Novels: the medium of recent Western tradition 5:30 The 18th-century bildungsroman 9:47 “Conservative” themes 16:18 The American dream in My Ántonia 22:39 Miraculous realism in Peace Like a River 29:02 Acknowledging the existence of evil 31:44 Wonder and encounter over strict interpretation 37:03 Revisiting works from your school years 38:47 Why narrative works 42:01 Books that nearly made the cut Links: 13 Novels Conservatives Will Love (but Probably Haven't Read) by Christopher Scalia Christopher J. Scalia at American Enterprise Institute The History of Rasselas by Samuel Johnson (1759) Evelina by Frances Burney (1778) Waverley by Sir Walter Scott (1814) The Blithedale Romance by Nathaniel Hawthorne (1852) Daniel Deronda by George Eliot (1876) My Ántonia by Willa Cather (1918) Their Eyes Were Watching God by Zora Neale Hurston (1937) The Girls of Slender Means by Muriel Spark (1963) The Children of Men by P. D. James (1992) Peace Like a River by Leif Enger (2001) Gilead by Marilynne Robinson (2004) The Road by Cormac McCarthy (2006) How I Won a Nobel Prize: A Novel by Julius Taranto (2023) Also on the Forum: Heights Forum Book Reviews On Reading Literature by Joseph Bissex Some Summer Reading Recommendations for Teachers by Tom Cox Modern Literature: On Curating the Contemporary featuring Mike Ortiz Guiding Our Boys through Modern Literature featuring Joe Breslin and Lionel Yaceczko Featured opportunities: Teaching Essentials Workshop at The Heights School (June 16-20, 2025) Convivium for Teaching Men at The Heights School (November 13-15, 2025)

THE HANDMAID'S TALE Season 6 Episode 10 - “The Handmaid's Tale” - June reflects on her experiences in Gilead and decides what to do next. (Disney/Steve Wilkie)ELISABETH MOSS, CHERRY JONES It's hard to say goodbye, but here we are—the final podcast for The Handmaid's Tale has arrived! Paul and Caroline dive deep into the 10th and final episode of Season 6, fittingly titled "The Handmaid's Tale." THE HANDMAID'S TALE Season 6 Episode 10 - “The Handmaid's Tale” - June reflects on her experiences in Gilead and decides what to do next. (Disney/Steve Wilkie)MADELINE BREWER After the thrilling climax of Episode 9, this finale took a quieter approach, focusing on resolution, emotional closure, and laying the groundwork for The Testaments, the upcoming sequel series based on Margaret Atwood's novel. Paul and Caroline generally appreciated the emotional payoff and the sense of closure for characters we've followed closely for eight years. But not in every case. THE HANDMAID'S TALE Season 6 Episode 10 - “The Handmaid's Tale” - June reflects on her experiences in Gilead and decides what to do next. (Disney/Steve Wilkie)YVONNE STRAHOVSKI They didn't shy away from highlighting some storytelling choices that didn't fully land. While not as critical as some online commenters, they felt that the finale spent a bit too much time on indulgent flashbacks and montages, time which could have been better used to deepen certain pivotal moments. (We're looking at you, Naomi.) THE HANDMAID'S TALE Season 6 Episode 10 - “The Handmaid's Tale” - June reflects on her experiences in Gilead and decides what to do next. (Disney/Steve Wilkie)ALEXIS BLEDEL, ELISABETH MOSS Still, the journey has been incredible, and both hosts agree the finale succeeded in leaving us hungry for what's next. Paul and Caroline will definitely return to cover The Testaments when it premieres. Season 6: 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 | 609 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410+Bruce Miller Interview Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

Christiane und Hanna besprechen in der neuen Podcast-Episode die neunte und zehnte Folge der dystopischen Dramaserie The Handmaid's Tale. Direkt nach dem Massaker an den Kommandeuren setzt die Handlung ein und führt bis zum großen Staffelfinale der Serie. Wird June (Elisabeth Moss) auf der Suche nach ihrer Tochter Hannah ihre Mutter und zweite Tochter Nichole wiedersehen? Eine lang vermisste Freundin taucht erneut auf und in einer wunderschönen Rückblicksequenz sehen wir einen Karaoke-Abend ohne der Existenz von Gilead.Was wird aus Aunt Lydia (Ann Dowd) und welche Rolle könnte sie in dem neuen Spin-off The Testaments spielen? Werden Serena (Yvonne Strahovski) und June sich vertragen oder sie ihr sogar vergeben? Und warum sind ein Stuhl, ein Tisch und eine Lampe relevant?Timestamps:0:00:00 Folge 90:25:30 Folge 10ANZEIGE:Nur bei MagentaTV gibt's die spektakuläre finale Staffel von „The Handmaid's Tale“, wo Ihr jeden Dienstag eine neue Folge seht - immer zeitgleich zur US-Premiere) Natürlich könnt ihr auch alle vorherigen Staffeln bei MagentaTV streamen.de/unterhaltung/serien-und-filme/original-und-exklusivserien/the-handmaids-tale ChristianeBluesky: https://bsky.app/profile/christianeattig.deHanna Bluesky: https://bsky.app/profile/mediawhore.bsky.social Instagram: https://www.instagram.com/mediawhore Hosted on Acast. See acast.com/privacy for more information.

Dr. Tom Curran continues to discuss 18 scripture passages that will change your life. Tom shares several insights from Song of Songs chapters 4-6 about how much Jesus loves YOU!You have ravished my heart, my sister, my bride; you have ravished my heart with one glance of your eyes, with one bead of your necklace. (Song of Songs 4: 9)Turn your eyes away from me, for they stir me up. Your hair is like a flock of goats streaming down from Gilead. (Song of Songs 6: 5)

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Nvidias neuen KI-Billigchip, Hoffen auf das Pharma-Revival und was diese Woche sonst noch wichtig wird. Außerdem geht es um VanEck Uranium and Nuclear Technologies ETF (WKN: A3D47K), Uranium Energy, Oklo, Nuscale, Health Care Select Sector SPDR (WKN: A14QB2), CVS Health, United Health Group, Eli Lilly, Cigna, Danaher, Thermo Fisher Scientific sowie Gilead, Sandoz, J&J, Roche, Sanofi, VanEck Quantum Computing ETF (WKN: A418QM) Google, IBM, Microsoft, Sony, Boeing, Honeywell, IonQ, Rigetti und D-Wave. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)JOSH CHARLES The penultimate episode of The Handmaid's Tale (season 6 episode 9) wasn't just good—it was fantastic. Paul and Caroline are back with an energized breakdown of Episode 9, “Execution,” and they're thrilled to share their reactions with you. After years of suffering alongside these characters, this episode delivered some long-awaited justice and catharsis. Paul and Caroline loved every moment—but they still put on their podcasting hats to ensure the plot wasn't just emotionally satisfying, but also logically sound. Thankfully, "Execution" nailed both. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)BRADLEY WHITFORD This week's podcast mirrors the intense pacing of the episode, taking you step-by-step through all the dramatic twists leading up to the unforgettable scenes at the gallows and the explosive start of the rebellion. From there, the discussion shifts toward Commander Lawrence's tense, fateful journey to the airport and the dramatic consequences that followed. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)MAX MINGHELLA Paul and Caroline found this episode to be a nearly perfect balance of tension, emotional payoff, and narrative clarity—the kind of episode fans have waited seasons to see. Join them as they celebrate these pivotal moments and dissect every significant plot turn. THE HANDMAID'S TALE Season 6 Episode 9 - “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)D'ARCY CARDEN, SAM JAEGER THE HANDMAID'S TALE Season 6 Episode 9- “Execution” - June faces her biggest challenge as Gilead cracks down on the rebels. (Disney/Steve Wilkie)SAMIRA WILEY Season 6: 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410+Bruce Miller Interview Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

One of Bowyer Research’s clients, financial advisor David Bahnsen, recently spoke at Gilead Sciences’ annual meeting in defense of a shareholder proposal asking the company to eschew divisive DEI quotas in its supplier policies. We’re presenting the speech here for our listeners. Learn more about The Bahnsen Group here.See omnystudio.com/listener for privacy information.

This week on The TV Dudes, Les is joined by actress Carey Cox, who portrays Rose Blaine in The Handmaid's Tale. Introduced in Season 5 as the wife of Nick, Rose is an unusual character in Gilead due to her visible disability — congenital hip dysplasia. This mirrors Carey's real-life experience living with Ehlers-Danlos Syndrome. As a disabled actor and advocate, Carey brings authenticity and nuance to her roles, challenging outdated perceptions of disability in the entertainment industry. We chat about her career path, her work on The Handmaid's Tale, and much more. #TheHandmaidsTale #CareyCox #TheTVDudes 

THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie). The revolution has begun. In The Handmaid's Tale Season 6 Episode 8 "Exodus", the carefully plotted rebellion against Gilead erupts during Serena Joy's wedding, shifting the tide of power in ways we've long hoped—and feared. On this week's podcast, Paul and Caroline unpack the episode's three central storylines and what they mean for the final stretch of the series. The episode unfolds through three distinct perspectives: Serena's Wedding:It's the centerpiece of the rebellion. The plan to bomb Jezebels has been replaced with something quieter but just as deadly: poison. Serena's maroon wedding cake becomes a focal point—rich in symbolism, according to Paul and Caroline, who debate its possible meanings. The poison weakens the guests, setting the stage for the handmaids to strike later that night. But what comes next for Serena? In the final scenes inside her and Wharton's new home, we're left wondering: Is she a survivor, a pawn, or a player? THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)ELISABETH MOSS June's Command:June leads from the front, orchestrating the handmaids' infiltration and managing the rebellion in real time. Paul and Caroline discuss June's transformation into a true field general—steely, smart, and still deeply human. They also wrestle with the looming question: what does a “win” even look like for June at this point, and is it within reach? THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)THE HANDMAID'S TALE Aunt Lydia's Reckoning:The final storyline brings us to Aunt Lydia, whose breaking point finally arrives at the Red Center. Surrounded by Janine and the other handmaids, she is forced to confront the consequences of her life's work. In her quiet moments and subtle gestures, a transformation begins—one that may redefine her future in Gilead. THE HANDMAID'S TALE Season 6 Episode 8 - “Exodus” - June and Moira execute their dangerous plan. Serena makes a big commitment. (Disney/Steve Wilkie)THE HANDMAID'S TALE With explosive action, raw emotion, and thematic depth, “Exodus” delivers a powerful step toward the endgame. Paul and Caroline are here to guide you through every decision, every cost, and every unanswered question. Season 6: 601 | 602 | 603 | 604 | 605 | 606 | 607 SEASON 5: 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 Season 4: 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 Season 3: 301+302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 Follow the Show On Hulu | Facebook | Our Facebook Group | X Follow the Hosts on X Caroline | Paul Music: “Ominous Ambience” by Viljami Mehto, licensed by Pod Clubhouse. This podcast was recorded, edited, and produced by Paul and Caroline Daley at Pod Clubhouse Studios and is a Pod Clubhouse Original Production.

This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

In this week's episode we're back with our recaps of The Handmaid's Tale. In its final season, we will recap each and every episode. This week we are recapping episode 608 of the series. Based on the best-selling novel by Margaret Atwood, this series is set in Gilead, a totalitarian society in what used to be part of the United States. Gilead is ruled by a fundamentalist regime that treats women as property of the state, and is faced with environmental disasters and a plummeting birth rate. In a desperate attempt to repopulate a devastated world, the few remaining fertile women are forced into sexual servitude. One of these women, Offred, is determined to survive the terrifying world she lives in, and find the daughter that was taken from her.              Host: Angelica Monk and Stacey Yvonne Music by: Sammus Edited by: Jamie Broadnax